These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 17684133)

  • 1. Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk?
    Murta-Nascimento C; Silverman DT; Kogevinas M; García-Closas M; Rothman N; Tardón A; García-Closas R; Serra C; Carrato A; Villanueva C; Dosemeci M; Real FX; Malats N
    Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1595-600. PubMed ID: 17684133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
    García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
    Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutathione S-transferase mu1 and N-acetyltransferase 2 genetic polymorphisms and exposure to tobacco smoke in nonsmoking and smoking lung cancer patients and population controls.
    Nyberg F; Hou SM; Hemminki K; Lambert B; Pershagen G
    Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):875-83. PubMed ID: 9796632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
    Okkels H; Sigsgaard T; Wolf H; Autrup H
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China.
    Song DK; Xing DL; Zhang LR; Li ZX; Liu J; Qiao BP
    Cancer Detect Prev; 2009; 32(5-6):416-23. PubMed ID: 19303722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women.
    McGrath M; Michaud D; De Vivo I
    BMC Cancer; 2006 Oct; 6():239. PubMed ID: 17026750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors.
    Schroeder JC; Conway K; Li Y; Mistry K; Bell DA; Taylor JA
    Cancer Res; 2003 Nov; 63(21):7530-8. PubMed ID: 14612556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population.
    Hung RJ; Boffetta P; Brennan P; Malaveille C; Hautefeuille A; Donato F; Gelatti U; Spaliviero M; Placidi D; Carta A; Scotto di Carlo A; Porru S
    Int J Cancer; 2004 Jul; 110(4):598-604. PubMed ID: 15122594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential interactions between GSTM1 and NAT2 genotypes on aromatic DNA adduct level and HPRT mutant frequency in lung cancer patients and population controls.
    Hou SM; Fält S; Yang K; Nyberg F; Pershagen G; Hemminki K; Lambert B
    Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):133-40. PubMed ID: 11219770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis.
    Kim WJ; Lee HL; Lee SC; Kim YT; Kim H
    J Urol; 2000 Jul; 164(1):209-13. PubMed ID: 10840461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10.
    Cascorbi I; Roots I; Brockmöller J
    Cancer Res; 2001 Jul; 61(13):5051-6. PubMed ID: 11431340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study.
    Matic M; Pekmezovic T; Djukic T; Mimic-Oka J; Dragicevic D; Krivic B; Suvakov S; Savic-Radojevic A; Pljesa-Ercegovac M; Tulic C; Coric V; Simic T
    Urol Oncol; 2013 Oct; 31(7):1184-92. PubMed ID: 24075358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk.
    Zhao H; Lin J; Grossman HB; Hernandez LM; Dinney CP; Wu X
    Int J Cancer; 2007 May; 120(10):2208-13. PubMed ID: 17290402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary intake of vegetables and fruits and the modification effects of GSTM1 and NAT2 genotypes on bladder cancer risk.
    Lin J; Kamat A; Gu J; Chen M; Dinney CP; Forman MR; Wu X
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2090-7. PubMed ID: 19549811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effect of smoking and inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 on bladder cancer in a Tunisian population.
    Rouissi K; Ouerhani S; Marrakchi R; Ben Slama MR; Sfaxi M; Ayed M; Chebil M; El Gaaied AB
    Cancer Genet Cytogenet; 2009 Apr; 190(2):101-7. PubMed ID: 19380028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GSTM1 and NAT2 polymorphisms and colon, lung and bladder cancer risk: a case-control study.
    Zupa A; Sgambato A; Bianchino G; Improta G; Grieco V; LA Torre G; Campisi B; Traficante A; Aieta M; Cittadini A
    Anticancer Res; 2009 May; 29(5):1709-14. PubMed ID: 19443391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk.
    Brockmöller J; Cascorbi I; Kerb R; Roots I
    Cancer Res; 1996 Sep; 56(17):3915-25. PubMed ID: 8752158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphism of glutathione S-transferases M1 and T1 as a risk factor in lung and bladder cancers.
    Salagovic J; Kalina I; Stubna J; Habalová V; Hrivnák M; Valanský L; Kohút A; Biros E
    Neoplasma; 1998; 45(5):312-7. PubMed ID: 9921921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis.
    Moore LE; Baris DR; Figueroa JD; Garcia-Closas M; Karagas MR; Schwenn MR; Johnson AT; Lubin JH; Hein DW; Dagnall CL; Colt JS; Kida M; Jones MA; Schned AR; Cherala SS; Chanock SJ; Cantor KP; Silverman DT; Rothman N
    Carcinogenesis; 2011 Feb; 32(2):182-9. PubMed ID: 21037224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility.
    Safarinejad MR; Safarinejad S; Shafiei N; Safarinejad S
    Urol Oncol; 2013 Oct; 31(7):1193-203. PubMed ID: 22154357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.